A Double-blind, Randomized, Placebo- and Active-controlled, Parallel-group Trial to Evaluate the Effect of Single-dose TMC207 on the QT/QTc Interval in Healthy Subjects.

Trial Profile

A Double-blind, Randomized, Placebo- and Active-controlled, Parallel-group Trial to Evaluate the Effect of Single-dose TMC207 on the QT/QTc Interval in Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Nov 2012

At a glance

  • Drugs Bedaquiline; Moxifloxacin
  • Indications Acute exacerbations of chronic bronchitis; Acute sinusitis; Bacterial infections; Community-acquired pneumonia; Intra-abdominal infections; Respiratory tract infections; Skin and soft tissue infections; Tuberculosis
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Nov 2011 Actual initiation date changed from Mar 2011 to Feb 2011 as reported by ClinicalTrials.gov.
    • 26 Apr 2011 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top